Literature DB >> 29109505

Response to Liu et al.

Kohtaro Ooka1, James J Connolly1, Joseph K Lim2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29109505     DOI： 10.1038/ajg.2017.292

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  4 in total

1.  Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.

Authors:  Kohtaro Ooka; James J Connolly; Joseph K Lim
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

2.  Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents.

Authors:  A M Moon; P K Green; K Berry; G N Ioannou
Journal:  Aliment Pharmacol Ther       Date:  2017-03-08       Impact factor: 8.171

3.  Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-03-15

4.  Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.

Authors:  Albert Do; Yash Mittal; AnnMarie Liapakis; Elizabeth Cohen; Hong Chau; Claudia Bertuccio; Dana Sapir; Jessica Wright; Carol Eggers; Kristine Drozd; Maria Ciarleglio; Yanhong Deng; Joseph K Lim
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.